Management of asynchronous multifocal adult glioblastoma with loss of BRAFV600E -mutant clonality: a case report

Abstract Glioblastoma (GBM) classification involves a combination of histological and molecular signatures including IDH1/2 mutation, TERT promoter mutation, and EGFR amplification. Non-canonical mutations such as BRAFV600E, found in 1–2% of GBMs, activate the MEK-ERK signaling pathway. This mutatio...

Full description

Saved in:
Bibliographic Details
Main Authors: Hannah Haile, Pavan S. Upadhyayula, Esma Karlovich, Michael B. Sisti, Brian J. A. Gill, Laura E. Donovan
Format: Article
Language:English
Published: BMC 2025-01-01
Series:Acta Neuropathologica Communications
Subjects:
Online Access:https://doi.org/10.1186/s40478-024-01894-w
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832571152172580864
author Hannah Haile
Pavan S. Upadhyayula
Esma Karlovich
Michael B. Sisti
Brian J. A. Gill
Laura E. Donovan
author_facet Hannah Haile
Pavan S. Upadhyayula
Esma Karlovich
Michael B. Sisti
Brian J. A. Gill
Laura E. Donovan
author_sort Hannah Haile
collection DOAJ
description Abstract Glioblastoma (GBM) classification involves a combination of histological and molecular signatures including IDH1/2 mutation, TERT promoter mutation, and EGFR amplification. Non-canonical mutations such as BRAFV600E, found in 1–2% of GBMs, activate the MEK-ERK signaling pathway. This mutation can be targeted by small molecule inhibitors, offering therapeutic potential for GBM. In this case report, we describe the management of a 67-year-old male with BRAFV600E -mutant GBM, who experienced both local clonal and distant non-clonal BRAFV600E -mutant recurrences. Initial treatment involved surgical resection followed by radiotherapy and temozolomide (TMZ). Subsequent recurrences were managed with re-resection and dabrafenib/trametinib combination therapy. Notably, a new, non-clonal BRAFV600E -negative tumor developed in a distant location, highlighting the challenge of clonal evolution and resistance in GBM management. The patient’s disease ultimately progressed despite multiple lines of therapy, including targeted inhibition. Identifying mechanisms of resistance and tailoring flexible treatment approaches are essential for advancing outcomes in BRAFV600E -mutant GBM. This case emphasizes the value of molecular profiling in personalizing treatment for patients with multifocal disease. The evolving nature of these tumors requires persistent clinical monitoring and treatment adjustments based on tissue diagnostics.
format Article
id doaj-art-29a92b0c4c3a44df814f6ca65ac9a90e
institution Kabale University
issn 2051-5960
language English
publishDate 2025-01-01
publisher BMC
record_format Article
series Acta Neuropathologica Communications
spelling doaj-art-29a92b0c4c3a44df814f6ca65ac9a90e2025-02-02T12:47:09ZengBMCActa Neuropathologica Communications2051-59602025-01-011311510.1186/s40478-024-01894-wManagement of asynchronous multifocal adult glioblastoma with loss of BRAFV600E -mutant clonality: a case reportHannah Haile0Pavan S. Upadhyayula1Esma Karlovich2Michael B. Sisti3Brian J. A. Gill4Laura E. Donovan5Department of Neurological Surgery, Columbia University Irving Medical CenterDepartment of Neurological Surgery, Columbia University Irving Medical CenterDepartment of Pathology and Cell Biology, Columbia University Irving Medical CenterDepartment of Neurological Surgery, Columbia University Irving Medical CenterDepartment of Neurological Surgery, Columbia University Irving Medical CenterDepartment of Neuro-Oncology, Columbia University Irving Medical CenterAbstract Glioblastoma (GBM) classification involves a combination of histological and molecular signatures including IDH1/2 mutation, TERT promoter mutation, and EGFR amplification. Non-canonical mutations such as BRAFV600E, found in 1–2% of GBMs, activate the MEK-ERK signaling pathway. This mutation can be targeted by small molecule inhibitors, offering therapeutic potential for GBM. In this case report, we describe the management of a 67-year-old male with BRAFV600E -mutant GBM, who experienced both local clonal and distant non-clonal BRAFV600E -mutant recurrences. Initial treatment involved surgical resection followed by radiotherapy and temozolomide (TMZ). Subsequent recurrences were managed with re-resection and dabrafenib/trametinib combination therapy. Notably, a new, non-clonal BRAFV600E -negative tumor developed in a distant location, highlighting the challenge of clonal evolution and resistance in GBM management. The patient’s disease ultimately progressed despite multiple lines of therapy, including targeted inhibition. Identifying mechanisms of resistance and tailoring flexible treatment approaches are essential for advancing outcomes in BRAFV600E -mutant GBM. This case emphasizes the value of molecular profiling in personalizing treatment for patients with multifocal disease. The evolving nature of these tumors requires persistent clinical monitoring and treatment adjustments based on tissue diagnostics.https://doi.org/10.1186/s40478-024-01894-wGlioblastomaBRAFV600EBRAF inhibitorsClonal evolutionTargeted therapyGlioma
spellingShingle Hannah Haile
Pavan S. Upadhyayula
Esma Karlovich
Michael B. Sisti
Brian J. A. Gill
Laura E. Donovan
Management of asynchronous multifocal adult glioblastoma with loss of BRAFV600E -mutant clonality: a case report
Acta Neuropathologica Communications
Glioblastoma
BRAFV600E
BRAF inhibitors
Clonal evolution
Targeted therapy
Glioma
title Management of asynchronous multifocal adult glioblastoma with loss of BRAFV600E -mutant clonality: a case report
title_full Management of asynchronous multifocal adult glioblastoma with loss of BRAFV600E -mutant clonality: a case report
title_fullStr Management of asynchronous multifocal adult glioblastoma with loss of BRAFV600E -mutant clonality: a case report
title_full_unstemmed Management of asynchronous multifocal adult glioblastoma with loss of BRAFV600E -mutant clonality: a case report
title_short Management of asynchronous multifocal adult glioblastoma with loss of BRAFV600E -mutant clonality: a case report
title_sort management of asynchronous multifocal adult glioblastoma with loss of brafv600e mutant clonality a case report
topic Glioblastoma
BRAFV600E
BRAF inhibitors
Clonal evolution
Targeted therapy
Glioma
url https://doi.org/10.1186/s40478-024-01894-w
work_keys_str_mv AT hannahhaile managementofasynchronousmultifocaladultglioblastomawithlossofbrafv600emutantclonalityacasereport
AT pavansupadhyayula managementofasynchronousmultifocaladultglioblastomawithlossofbrafv600emutantclonalityacasereport
AT esmakarlovich managementofasynchronousmultifocaladultglioblastomawithlossofbrafv600emutantclonalityacasereport
AT michaelbsisti managementofasynchronousmultifocaladultglioblastomawithlossofbrafv600emutantclonalityacasereport
AT brianjagill managementofasynchronousmultifocaladultglioblastomawithlossofbrafv600emutantclonalityacasereport
AT lauraedonovan managementofasynchronousmultifocaladultglioblastomawithlossofbrafv600emutantclonalityacasereport